RESUMO
Compared with natural enzymes, nanozymes usually exhibit much lower catalytic activities, which limit the sensitivities of nanozyme-based immunoassays. Herein, several metal ions without enzyme-like activities were engineered onto Uio-66-NH2 nanozyme through postsynthetic modification. The obtained Mn+@Uio-66-NH2 (Mn+ = Zn2+, Cd2+, Co2+, Ca2+and Ni2+) exhibited improved phosphatase-like catalytic activities. In particular, a 12-fold increase in the catalytic efficiency (kcat/Km) of Uio-66-NH2 was observed after the modification with Zn2+. Mechanism investigations indicate that both the amino groups and oxygen-containing functional groups in Uio-66-NH2 are the binding sites of Zn2+, and the modified Zn2+ ions on Uio-66-NH2 serve as the additional catalytic sites for improving the catalytic performance. Furthermore, the highly active Zn2+@Uio-66-NH2 was used as a nanozyme label to develop a fluorescence immunoassay method for the detection of cardiac troponin I (cTnI). Compared with pristine Uio-66-NH2, Zn2+@Uio-66-NH2 can widen the linear range by 1 order of magnitude (from 10 pg/mL-1 µg/mL to 1 pg/mL-1 µg/mL) and also lower the detection limit by 5 times (from 4.7 pg/mL to 0.9 pg/mL).
Assuntos
Estruturas Metalorgânicas , Monoéster Fosfórico Hidrolases , Ácidos Ftálicos , Troponina I , Fluorescência , Metais , ÍonsRESUMO
The zirconium-amino acid framework MIP-202(Zr) was reported as a green phosphatase-like nanozyme for the first time. Moreover, its phosphatase-like activity can be inhibited by phosphate-containing drugs. Based on this finding, a universal fluorimetric strategy for sensing phosphate-containing drugs was developed. The detection limit was as low as 2 ng mL-1 for the model drug alendronate sodium. This strategy exhibits excellent selectivity over other non-phosphate-containing drugs and will broaden the applications of phosphatase-like nanozymes in clinical pharmacy.
